Mesenchymal Stromal cells and viral infection

Stem Cells International

Volumn 2015, Issue , 2015, Pages

  Thanunchai, Maytawan ^a   Hongeng, Suradej ^a   Thitithanyanont, Arunee ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Mahidol University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LUNG INJURY; ADIPOSE DERIVED STEM CELL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIMICROBIAL ACTIVITY; APOPTOSIS; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; EFFECTOR CELL; END STAGE LIVER DISEASE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEART INFARCTION; HEPATITIS B; HEPATITIS B VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; INFLUENZA A; INFLUENZA A (H5N1); INFLUENZA A (H7N9); INFLUENZA A (H9N2); INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N9; INFLUENZA VIRUS A H9N2; KAPOSI SARCOMA; LIVER CELL; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MESENCHYMAL STROMA CELL TRANSPLANTATION; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TISSUE REGENERATION; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS STRAIN; VIRUS VIRULENCE;

EID: 84939161801     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2015/860950     Document Type: Review

References (76)

1. A. Augello, T. B. Kurth, and C. de Bari, "Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches, " European Cells and Materials, vol. 20, pp. 121-133, 2010.
2. G. Chamberlain, J. Fox, B. Ashton, and J. Middleton, "Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing, " Stem Cells, vol. 25, no. 11, pp. 2739-2749, 2007.
3. M. Crisan, S. Yap, L. Casteilla et al. , "A perivascular origin for mesenchymal stem cells in multiple human organs, " Cell Stem Cell, vol. 3, no. 3, pp. 301-313, 2008.
4. M. Dominici, K. Le Blanc, I. Mueller et al. , "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for CellularTherapy position statement, " Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
5. A. Uccelli, L. Moretta, and V. Pistoia, "Mesenchymal stem cells in health and disease, " Nature Reviews Immunology, vol. 8, no. 9, pp. 726-736, 2008.
6. F.-J. Lv, R. S. Tuan, K. M. C. Cheung, and V. Y. L. Leung, "Concise review: the surface markers and identity of human mesenchymal stem cells, " Stem Cells, vol. 32, no. 6, pp. 1408-1419, 2014.
7. K. Le Blanc, "Mesenchymal stromal cells: tissue repair and immune modulation, " Cytotherapy, vol. 8, no. 6, pp. 559-561, 2006.
8. D. Zipori, "Mesenchymal stem cells: harnessing cell plasticity to tissue and organ repair, " Blood Cells, Molecules, and Diseases, vol. 33, no. 3, pp. 211-215, 2004.
9. X. Wei, X. Yang, Z.-P. Han, F.-F. Qu, L. Shao, and Y.-F. Shi, "Mesenchymal stem cells: a new trend for cell therapy, " Acta Pharmacologica Sinica, vol. 34, no. 6, pp. 747-754, 2013.
10. L. Peng, D.-Y. Xie, B.-L. Lin et al. , "Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes, " Hepatology, vol. 54, no. 3, pp. 820-828, 2011.
11. P. Kharaziha, P. M. HellstrÖm, B. Noorinayer et al. , "Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial, " European Journal of Gastroenterology and Hepatology, vol. 21, no. 10, pp. 1199-1205, 2009.
12. J. Pak, J.-J. Chang, J. H. Lee, and S. H. Lee, "Safety reporting on implantation of autologous adipose tissue-derived stemcells with platelet-rich plasma into human articular joints, " BMC Musculoskeletal Disorders, vol. 14, article 337, 2013.
13. D. Garcia-Olmo, D. Herreros, M. Pascual et al. , "Treatment of enterocutaneous fistula in Crohns Disease with adiposederived stem cells: a comparison of protocols with and without cell expansion, " International Journal of Colorectal Disease, vol. 24, no. 1, pp. 27-30, 2009.
14. M. Tobita, H. Orbay, and H. Mizuno, "Adipose-derived stem cells: current findings and future perspectives, " Discovery Medicine, vol. 11, no. 57, pp. 160-170, 2011.
15. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses, " Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
16. A. Corcione, F. Benvenuto, E. Ferretti et al. , "Humanmesenchymal stem cells modulate B-cell functions, " Blood, vol. 107, no. 1, pp. 367-372, 2006.
17. X.-X. Jiang, Y. Zhang, B. Liu et al. , "Humanmesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells, " Blood, vol. 105, no. 10, pp. 4120-4126, 2005.
18. I. Rasmusson, M. Uhlin, K. Le Blanc, and V. Levitsky, "Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes, " Journal of Leukocyte Biology, vol. 82, no. 4, pp. 887-893, 2007.
19. G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta, "Mesenchymal stem cell-natural killer cell interactions: Eevidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation, " Blood, vol. 107, no. 4, pp. 1484-1490, 2006.
20. M. Krampera, L. Cosmi, R. Angeli et al. , "Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells, " Stem Cells, vol. 24, no. 2, pp. 386-398, 2006.
21. R. Meisel, A. Zibert, M. Laryea, U. GÖbel, W. Daubener, and D. Dilloo, "Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenasemediated tryptophan degradation, " Blood, vol. 103, no. 12, pp. 4619-4621, 2004.
22. K. Nemeth, A. Leelahavanichkul, P. S. T. Yuen et al. , "Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production, " Nature Medicine, vol. 15, no. 1, pp. 42-49, 2009.
23. W. T. Tse, J. D. Pendleton, W. M. Beyer, M. C. Egalka, and E. C. Guinan, "Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation, " Transplantation, vol. 75, no. 3, pp. 389-397, 2003.
24. F. Baron and R. Storb, "Mesenchymal stromal cells: a new tool against graft-versus-host disease?" Biology of Blood andMarrow Transplantation, vol. 18, no. 6, pp. 822-840, 2012.
25. E. Dander, G. Lucchini, P. Vinci et al. , "Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring, " Leukemia, vol. 26, no. 7, pp. 1681-1684, 2012.
26. G. H. Martinho, R. M. C. Romanelli, G. M. Teixeira, A. V. Macedo, J. M. C. Chaia, and V. Nobre, "Infectious complications associated with the use of central venous catheters in patients undergoing hematopoietic stem cell transplantation, " The American Journal of Infection Control, vol. 41, no. 7, pp. 642-644, 2013.
27. L. von Bahr, B. Sundberg, L. LÖnnies et al. , "Long-term complications, immunologic effects, and role of passage for outcome inmesenchymal stromal cell therapy, " Biology of Blood and Marrow Transplantation, vol. 18, no. 4, pp. 557-564, 2012.
28. F. J. Jenkins, D. T. Rowe, and C. R. Rinaldo Jr. , "Herpesvirus infections in organ transplant recipients, " Clinical and Diagnostic Laboratory Immunology, vol. 10, no. 1, pp. 1-7, 2003.
29. J. A. Fishman, "Overview: cytomegalovirus and the herpesviruses in transplantation, " American Journal of Transplantation, vol. 13, supplement 3, pp. 1-8, 2013.
30. S. V. Smirnov, R. Harbacheuski, A. Lewis-Antes, H. Zhu, P. Rameshwar, and S. V. Kotenko, "Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: implications for hematopoiesis, self-renewal and differentiation potential, " Virology, vol. 360, no. 1, pp. 6-16, 2007.
31. R. Meisel, K. Heseler, J. Nau et al. , "Cytomegalovirus infection impairs immunosuppressive and antimicrobial effector functions of human multipotent mesenchymal stromal cells, " Mediators of Inflammation, vol. 2014, Article ID898630, 7 pages, 2014.
32. M. A. Soland, L. R. Keyes, R. Bayne et al. , "Perivascular stromal cells as a potential reservoir of human cytomegalovirus, " American Journal of Transplantation, vol. 14, no. 4, pp. 820-830, 2014.
33. S. Avanzi, V. Leoni, A. Rotola et al. , "Susceptibility of human placenta derived mesenchymal stromal/stem cells to human herpesviruses infection, " PLoS ONE, vol. 8, no. 8, Article ID e71412, 2013.
34. M. Sundin, A. Lindblom, C. Örvell et al. , "Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation, " Biology of Blood and Marrow Transplantation, vol. 14, no. 10, pp. 1172-1179, 2008.
35. R. Rollin, R. Alvarez-Lafuente, F. Marco et al. , "Human parvovirus B19, varicella zoster virus, and human herpesvirus-6 in mesenchymal stem cells of patients with osteoarthritis: analysis with quantitative real-time polymerase chain reaction, " Osteoarthritis and Cartilage, vol. 15, no. 4, pp. 475-478, 2007.
36. A. A. Okoye and L. J. Picker, "CD4+ T-cell depletion in HIV infection: mechanisms of immunological failure, " Immunological Reviews, vol. 254, no. 1, pp. 54-64, 2013.
37. O. Allam, S. Samarani, and A. Ahmad, "Mesenchymal stem cell therapy in HIV-infected HAART-treated nonimmune responders restores immune competence, " AIDS, vol. 27, no. 8, pp. 1349-1352, 2013.
38. L. Wang, D. Mondal, V. F. La Russa, and K. C. Agrawal, "Suppression of clonogenic potential of human bone marrow mesenchymal stemcellsbyHIVtype 1: putative role ofHIVtype 1 Tat protein and inflammatory cytokines, " AIDS Research and Human Retroviruses, vol. 18, no. 13, pp. 917-931, 2002.
39. E. J. Cotter, N. Chew, W. G. Powderly, and P. P. Doran, "HIV type 1 altersmesenchymal stem cell differentiation potential and cell phenotype ex vivo, "AIDS Research andHuman Retroviruses, vol. 27, no. 2, pp. 187-199, 2011.
40. D. Gibellini, F. Alviano, A. Miserocchi et al. , "HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells, " Retrovirology, vol. 8, article 40, 2011.
41. K. Cheng, P. Rai, X. Lan et al. , "Bone-derived mesenchymal stromal cells from HIV transgenic mice exhibit altered proliferation, differentiation capacity and paracrine functions along with impaired therapeutic potential in kidney injury, " Experimental Cell Research, vol. 319, no. 14, pp. 2266-2274, 2013.
42. R. Ma, Q. Xing, L. Shao et al. , "Hepatitis B virus infection and replication in human bone marrow mesenchymal stem cells, " Virology Journal, vol. 8, p. 486, 2011.
43. Y. Wang, F. Wang, H. Zhao, X. Zhang, H. Chen, and K. Zhang, "Human adipose-derived mesenchymal stem cells are resistant to HBV infection during differentiation into hepatocytes in vitro, " International Journal of Molecular Sciences, vol. 15, no. 4, pp. 6096-6110, 2014.
44. K.-D. Lee, T. K.-C. Kuo, J. Whang-Peng et al. , "In vitro hepatic differentiation of human mesenchymal stem cells, " Hepatology, vol. 40, no. 6, pp. 1275-1284, 2004.
45. H.-L. Hang and Q. Xia, "Role of BMSCs in liver regeneration and metastasis after hepatectomy, " World Journal of Gastroenterology, vol. 20, no. 1, pp. 126-132, 2014.
46. C. Xie, Y.-B. Zheng, H.-P. Zhu, L. Peng, and Z.-L. Gao, "Human bone marrow mesenchymal stem cells are resistant to HBV infection during differentiation into hepatocytes in vivo and in vitro, " Cell Biology International, vol. 33, no. 4, pp. 493-500, 2009.
47. Q. Rong, L. Zhang, E. Su et al. , "Bone marrow-derived mesenchymal stem cells are capable of mediating hepatitis B virus infection in injured tissues, " Journal of Viral Hepatitis, vol. 15, no. 8, pp. 607-614, 2008.
48. Y.-S. Zhong, N. Lin, M.-H. Deng, F.-C. Zhang, Z.-F. Tang, and R.-Y. Xu, "Deficient proliferation of bone marrow-derived mesenchymal stem cells in patients with chronic hepatitis b viral infections and cirrhosis of the liver, " Digestive Diseases and Sciences, vol. 55, no. 2, pp. 438-445, 2010.
49. Y. P. Lin, M. Shaw, V. Gregory et al. , "Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 17, pp. 9654-9658, 2000.
50. Q. Liu, D.-Y. Liu, and Z.-Q. Yang, "Characteristics of human infection with avian influenza viruses and development of new antiviral agents, " Acta Pharmacologica Sinica, vol. 34, no. 10, pp. 1257-1269, 2013.
51. T. T. Thanh, H. R. van Doorn, and M. D. de Jong, "HumanH5N1 influenza: current insight into pathogenesis, " International Journal of Biochemistryand Cell Biology, vol. 40, no. 12, pp. 2671-2674, 2008.
52. M. D. de Jong, C. P. Simmons, T. T. Thanh et al. , "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia, " Nature Medicine, vol. 12, no. 10, pp. 1203-1207, 2006.
53. G. Sharma, D. C. Sharma, L. H. Fen et al. , "Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor, " Emerging Microbes and Infections, vol. 2, no. 8, 2013.
54. F. G. J. Calkoen, C. Vervat, A. G. S. van Halteren et al. , "Mesenchymal stromal cell therapy is associated with increased adenovirus-associated but not cytomegalovirusassociatedmortality in children with severe acute graft-versushost disease, " StemCells TranslationalMedicine, vol. 3, no. 8, pp. 899-910, 2014.
55. G. Lucchini, E. Dander, F. Pavan et al. , "Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation, " Stem Cells International, vol. 2012, Article ID 690236, 6 pages, 2012.
56. H. Karlsson, S. Samarasinghe, L. M. Ball et al. , "Mesenchymal stem cells exert differential effects on alloantigen and virusspecific T-cell responses, " Blood, vol. 112, no. 3, pp. 532-541, 2008.
57. M. Sundin, C. Örvell, I. Rasmusson, B. Sundberg, O. Ringden, and K. Le Blanc, "Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual, " Bone Marrow Transplantation, vol. 37, no. 11, pp. 1051-1059, 2006.
58. G. Malcherek, N. Jin, A. G. Huckelhoven et al. , "Mesenchymal stromal cells inhibit proliferation of virus-specificCD8+ Tcells, " Leukemia, vol. 28, no. 12, pp. 2388-2394, 2014.
59. X. Liu, T. Feng, T. Gong et al. , "Human umbilical cord mesenchymal stem cells inhibit the function of allogeneic activated Vγ9Vδ;2 T lymphocytes In Vitro, " BioMed Research International, vol. 2015, Article ID 317801, 10 pages, 2015.
60. M. E. J. Reinders, J. W. de Fijter, H. Roelofs et al. , "Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study, " Stem Cells Translational Medicine, vol. 2, no. 2, pp. 107-111, 2013.
61. O. Blennow, G. Fjaertoft, J. Winiarski, P. Ljungman, J. Mattsson, and M. Remberger, "Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis-the incidence remains high, " Biology of Blood and Marrow Transplantation, vol. 20, no. 10, pp. 1646-1649, 2014.
62. Y. Li, Y. Chi, Q. Bian, T. Wen, and W. Zhang, "Mesenchymal stem cells therapy for H9N2 avian influenza viruses induced acute lung injury in mice, " in Proceedings of the International Conference on Biomedical Engineering and Biotechnology (ICBEB 12), pp. 1052-1055, IEEE, Macau, China, May 2012.
63. I. Darwish, D. Banner, S. Mubareka et al. , "Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza, " PLoS ONE, vol. 8, no. 8, Article ID e71761, 2013.
64. J. E. Gotts, J. Abbott, and M. A. Matthay, "Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy, " The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 307, no. 5, pp. L395-L406, 2014.
65. M. Thanunchai, P. Kanrai, S. Wiboon-Ut, P. Puthavathana, S. Hongeng, and A. Thitithanyanont, "Tropism of avian influenza a (H5N1) virus to mesenchymal stemcells and CD34+ hematopoietic stem cells, " PLoS ONE, vol. 8, no. 12, Article ID e81805, 2013.
66. M. Khatri, T. D. OBrien, S. M. Goyal, and J. M. Sharma, "Isolation and characterization of chicken lung mesenchymal stromal cells and their susceptibility to avian influenza virus, " Developmental and Comparative Immunology, vol. 34, no. 4, pp. 474-479, 2010.
67. H. S. Kang, M. Habib, J. Chan et al. , "Aparadoxical role for IFN-γ in the immune properties of mesenchymal stem cells during viral challenge, " Experimental Hematology, vol. 33, no. 7, pp. 796-803, 2005.
68. W. Li, G. Ren, Y. Huang et al. , "Mesenchymal stem cells: a double-edged sword in regulating immune responses, " Cell Death and Differentiation, vol. 19, no. 9, pp. 1505-1513, 2012.
69. L. M. Ball, M. E. Bernardo, H. Roelofs et al. , "Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation, " Blood, vol. 110, no. 7, pp. 2764-2767, 2007.
70. Y. Fellig, G. Almogy, E. Galun, and M. Ketzinel-Gilad, "A hepatocellular carcinoma cell line producingmature hepatitis B viral particles, " Biochemical and Biophysical Research Communications, vol. 321, no. 2, pp. 269-274, 2004.
71. H. Aurich, M. Sgodda, P. Kaltwaβer et al. , "Hepatocyte differentiation ofmesenchymal stem cells fromhuman adipose tissue in vitro promotes hepatic integration in vivo, " Gut, vol. 58, no. 4, pp. 570-581, 2009.
72. L. E. Cavallin, P. Goldschmidt-Clermont, and E. A. Mesri, "Molecular and cellular mechanisms of KSHV oncogenesis of Kaposis sarcoma associated with HIV/AIDS, " PLoS Pathogens, vol. 10, no. 7, Article ID e1004154, 2014.
73. T. Jones, F. Ye, R. Bedolla et al. , "Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV, " The Journal of Clinical Investigation, vol. 122, no. 3, pp. 1076-1081, 2012.
74. C. H. Parsons, B. Szomju, and D. H. Kedes, "Susceptibility of human fetal mesencyhmal stem cells to Kaposi sarcomaassociated herpesvirus, " Blood, vol. 104, no. 9, pp. 2736-2738, 2004.
75. A. Krasnodembskaya, Y. Song, X. Fang et al. , "Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37, " Stem Cells, vol. 28, no. 12, pp. 2229-2238, 2010.
76. R. Meisel, S. Brockers, K. Heseler et al. , "Human but notmurine multipotentmesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2, 3-dioxygenase, " Leukemia, vol. 25, no. 4, pp. 648-654, 2011.